Core Insights - BriaCell Therapeutics Corp. has announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK) to accelerate the clinical development of its Bria-OTS+ platform, which includes Bria-BRES+ for breast cancer [1][2][4] Group 1: Collaboration Details - The collaboration will focus on manufacturing, Investigational New Drug (IND) development, and clinical protocol support for a Phase 1 clinical trial of Bria-BRES+ [2][3] - This partnership builds on BriaCell's previous selection into MSK's accelerator program, which aims to expedite the development of innovative cancer therapies [2][3] Group 2: Institutional Expertise - MSK, a leading cancer research and treatment institution with over 135 years of experience, will provide BriaCell access to its clinical and institutional expertise, including cell therapy manufacturing and IND preparation [3][7] - The collaboration is expected to enhance the development of Bria-OTS+, which is designed to address unmet medical needs in metastatic breast cancer and other cancer types [4][5] Group 3: Leadership Statements - BriaCell's President and CEO, Dr. William V. Williams, expressed enthusiasm about the collaboration, highlighting the urgent medical needs of metastatic breast cancer patients [4] - BriaCell's Chief Scientific Officer, Miguel Lopez-Lago, emphasized the potential of the Bria-OTS+ platform to transform cancer care through its unique mechanism of action [5]